NCT04672356 2023-06-22
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.